Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol

Area of Science:

• Pediatrics
• Dermatology
• Pharmacology

Background:

• Infantile hemangiomas (IHs) are common vascular tumors in infants, characterized by rapid proliferation followed by involution.
• IHs can lead to functional impairment or cosmetic disfigurement, necessitating timely and effective treatment.
• Early intervention is crucial for managing IHs and preventing long-term complications.

Purpose of the Study:

• To evaluate the efficacy and safety of oral propranolol for treating proliferating infantile hemangiomas in Japanese infants.
• To determine the resolution rate and identify potential adverse events associated with propranolol therapy in this population.

Main Methods:

• A prospective study involving 32 Japanese infants (1-4 months old) with proliferating IHs.
• Outpatient administration of oral propranolol, starting at 1 mg/kg/day and increasing to 2 mg/kg/day.
• Assessment of treatment success (complete or near-complete resolution) at week 25, with monitoring for adverse events.

Main Results:

• A success rate of 56% (18/32 patients) was observed at week 25.
• Six patients experienced recurrence after treatment cessation.
• Adverse events were reported in 16 patients, with no significant events during initial dose titration; one patient was hospitalized for pneumonia.

Conclusions:

• Oral propranolol at a dosage of 2 mg/kg/day demonstrates significant efficacy and a favorable safety profile for treating infantile hemangiomas in Japanese infants.
• Outpatient management with oral propranolol is a viable and effective strategy for IHs, though recurrence and adverse events require monitoring.